Zevra Therapeutics Profit Margin

Zevra Therapeutics (ZVRA) currently reports a profit margin of 52.8% as of September 2026. That compares with 40.83% in the prior-year period — up 29.3% year over year. That is above the Healthcare sector average of 19.13%. Use the charts on this page to explore Zevra Therapeutics's profit margin history and peer comparisons.

Zevra Therapeutics's profit margin increased from 40.83% to 52.8% — a 29.3% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Zevra Therapeutics's profit margin of 52.8% is higher than the Healthcare sector average of 19.13%. That is roughly 176.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Zevra Therapeutics's current 52.8% should be judged against Healthcare norms (sector average: 19.13%) and against ZVRA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 52.8%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.13%. From there, open related valuation or income-statement pages for Zevra Therapeutics, and consider following ZVRA for alerts when major investors trade the stock.